These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8740998)

  • 1. Evaluation of tacrine hydrochloride (Cognex) in two parallel-group studies.
    Gracon SI
    Acta Neurol Scand Suppl; 1996; 165():114-22. PubMed ID: 8740998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.
    Knapp MJ; Knopman DS; Solomon PR; Pendlebury WW; Davis CS; Gracon SI
    JAMA; 1994 Apr; 271(13):985-91. PubMed ID: 8139083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
    Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
    N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. The Tacrine 970-6 Study Group.
    Foster NL; Petersen RC; Gracon SI; Lewis K
    Dementia; 1996; 7(5):260-6. PubMed ID: 8872417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
    Farlow M; Gracon SI; Hershey LA; Lewis KW; Sadowsky CH; Dolan-Ureno J
    JAMA; 1992 Nov; 268(18):2523-9. PubMed ID: 1404819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
    Chatellier G; Lacomblez L
    BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, placebo-controlled study of tacrine in Chinese patients with Alzheimer's disease.
    Wong WJ; Liu HC; Fuh JL; Wang SJ; Hsu LC; Wang PN; Sheng WY
    Dement Geriatr Cogn Disord; 1999; 10(4):289-94. PubMed ID: 10364647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group.
    Knopman D; Schneider L; Davis K; Talwalker S; Smith F; Hoover T; Gracon S
    Neurology; 1996 Jul; 47(1):166-77. PubMed ID: 8710072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease.
    Farlow MR; Lahiri DK; Poirier J; Davignon J; Schneider L; Hui SL
    Neurology; 1998 Mar; 50(3):669-77. PubMed ID: 9521254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial.
    Maltby N; Broe GA; Creasey H; Jorm AF; Christensen H; Brooks WS
    BMJ; 1994 Apr; 308(6933):879-83. PubMed ID: 8173365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of tacrine hydrochloride (Cognex) in private practice.
    Howell GJ
    Acta Neurol Scand Suppl; 1996; 165():123-7. PubMed ID: 8740999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration.
    Burback D; Molnar FJ; St John P; Man-Son-Hing M
    Dement Geriatr Cogn Disord; 1999; 10(6):534-40. PubMed ID: 10559571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mixed-model analysis of incomplete longitudinal data from a high-dose trial of tacrine (Cognex) in Alzheimer's patients.
    Smith F
    J Biopharm Stat; 1996 Mar; 6(1):59-67. PubMed ID: 8838779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease.
    Raskind MA; Sadowsky CH; Sigmund WR; Beitler PJ; Auster SB
    Arch Neurol; 1997 Jul; 54(7):836-40. PubMed ID: 9236571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.
    Almkvist O; Jelic V; Amberla K; Hellström-Lindahl E; Meurling L; Nordberg A
    Dement Geriatr Cogn Disord; 2001; 12(1):22-32. PubMed ID: 11125238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of survival analysis techniques in evaluating the effect of long-term tacrine (Cognex) treatment on nursing home placement and mortality in patients with Alzheimer's disease.
    Smith F; Talwalker S; Gracon S; Srirama M
    J Biopharm Stat; 1996 Nov; 6(4):395-409. PubMed ID: 8969976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrine in Alzheimer's disease.
    Eagger SA; Levy R; Sahakian BJ
    Lancet; 1991 Apr; 337(8748):989-92. PubMed ID: 1673209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
    Antuono PG
    Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential role for estrogen replacement in the treatment of Alzheimer's dementia.
    Schneider LS; Farlow MR; Pogoda JM
    Am J Med; 1997 Sep; 103(3A):46S-50S. PubMed ID: 9344406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease.
    Schneider LS; Farlow MR; Henderson VW; Pogoda JM
    Neurology; 1996 Jun; 46(6):1580-4. PubMed ID: 8649552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.